<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03772457</url>
  </required_header>
  <id_info>
    <org_study_id>InV HT RAF 1010</org_study_id>
    <nct_id>NCT03772457</nct_id>
  </id_info>
  <brief_title>Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban</brief_title>
  <official_title>To Explore the Predictive Value of Infarction Volume on Hemorrhagic Transformation in Newly Diagnosed Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was aimed at patients with newly diagnosed stroke / TIA associated with
      nonvalvular atrial fibrillation. We will observe the effect of early using rivaroxaban
      anticoagulation on hemorrhagic transformation, and explore the predictive value of multi-mode
      MRI infarct volume / MMP-9 on hemorrhagic transformation after anticoagulation therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2019</start_date>
  <completion_date type="Anticipated">January 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Susceptibility weighted imaging(SWI) detection of newly developed hemorrhagic transformation after 14 days of rivaroxaban treatment</measure>
    <time_frame>14 days after enrolling</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Cerebrovascular Stroke</condition>
  <condition>Intracranial Hemorrhages</condition>
  <condition>Anticoagulant</condition>
  <condition>Matrix Metalloproteinases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>new oral anticoagulant molecules which is the selective factor Xa inhibitor</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed ischemic stroke/TIA patients with NVAF who sign the informed consent and
        receiveRivaroxaban treatment in the in-patient ward.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, ageâ‰¥18;

          2. Were newly diagnosed asischemic stroke/TIA concomitant NVAF;

          3. Prescribedand accept Rivaroxaban;

          4. Sign thewritten informed consent.

        Exclusion Criteria:

          1. Renal impairment (CrCl&lt;15 ml/min) or severe hepatic impairment.

          2. Significant hemorrhagic transformation (parenchymal hematoma type I or type II by the
             ECASS definition).

          3. Stroke or TIA caused by large artery atherosclerosis

          4. Planned major surgery or invasive intervention

          5. Active internal bleeding

          6. Malignancy or other serious medical conditions with a life expectancy &lt;6 months

          7. Allergery to Rivaroxaban

          8. Pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Lou, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Lou, PhD</last_name>
    <phone>13958007213</phone>
    <email>loumingxc@vip.sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Second Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MIN LOU, Ph.D.</last_name>
      <phone>8657187784811</phone>
      <email>loumingxc@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>MIN LOU, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>December 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2018</study_first_posted>
  <last_update_submitted>June 7, 2020</last_update_submitted>
  <last_update_submitted_qc>June 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

